SCHEMBL3290251

SCHEMBL3290251

CC1(C)CC1(Cn1cnc2c(N)ncnc21)OCP(=O)(O)O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.60
SLC22A6 Q4U2R8 2/20 0.60
CYP3A4 P08684 4/20 0.57
ENPP1 P22413 1/20 0.47
ADORA2A P29274 6/20 0.47
ADORA1 P30542 4/20 0.47
ADORA2B P29275 1/20 0.47
PI4KA P42356 1/20 0.46
PI4K2B Q8TCG2 1/20 0.46
PI4K2A Q9BTU6 1/20 0.46
PI4KB Q9UBF8 1/20 0.46
ABCB11 O95342 1/20 0.44
POLA1 P09884 1/20 0.44
POLG P54098 1/20 0.44
FAP Q12884 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ADCY1 Q08828 1/20 0.44
AHCY P23526 1/20 0.44
CYP2D6 P10635 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328650 0.85 CYP3A4 (0.48) FGFR1SLC22A6CYP3A4ADORA2AADORA1
SCHEMBL2904496 0.83 FGFR1 (0.61) FGFR1SLC22A6CYP3A4ENPP1ADORA2A
SCHEMBL5665238 0.82 FGFR1 (0.56) FGFR1SLC22A6CYP3A4ENPP1ADORA2A
SCHEMBL3293448 0.82 FGFR1 (0.56) FGFR1SLC22A6CYP3A4ENPP1ADORA2A
SCHEMBL2906659 0.81 ADORA2A (0.56) ADORA2AADORA1ADORA2BPI4KAPI4K2B
SCHEMBL4271570 0.81 FAP (0.69) FGFR1SLC22A6CYP3A4ENPP1ADORA2A
SCHEMBL2906275 0.81 POLB (0.38) FGFR1SLC22A6CYP3A4
SCHEMBL2913580 0.81 CYP3A4 (0.50) FGFR1SLC22A6CYP3A4ENPP1ADORA2A
SCHEMBL4273059 0.80 ADORA2A (0.47) FGFR1SLC22A6ADORA2AADORA1ADORA2B
SCHEMBL2906656 0.80 ADORA2A (0.55) ADORA2AADORA1ADORA2BPI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 US claimed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 US claimed
US-20060052346-A1 Nucleoside phosphonate derivatives useful in the treatment of HIV infections LG LIFE SCIENCES LTD. (KR) 2006-03-09 US claimed
US-20040063668-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2004-04-01 US claimed
US-7723319-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2010-05-25 US disclosed
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 US disclosed
US-7157448-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2007-01-02 US disclosed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 US disclosed
US-20060052346-A1 Nucleoside phosphonate derivatives useful in the treatment of HIV infections LG LIFE SCIENCES LTD. (KR) 2006-03-09 US disclosed
US-20040063668-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052346-A1 Nucleoside phosphonate derivatives useful in the treatment of HIV infections PNP, TYMP, ENTPD5 FGFR1 3684/4885SLC22A6 989/4885CYP3A4 1213/4885
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same PNP, ITPA, MTAP FGFR1 3435/4885SLC22A6 1234/4885CYP3A4 456/4885
US-20040063668-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same PNP, ITPA, MTAP FGFR1 3435/4885SLC22A6 1234/4885CYP3A4 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.